It appears as though CRSP is forming a micro ascending triangle that is likely to result in bullish momentum....
The Williams Alligator is widening to the upside and there was recently a bullish cross.
This is inherently bullish, but could always change in an instant....
NASDAQ:MGX
here's an analysis of Metagenomi, Inc.: Chart Data is limited..
Financial Performance:
Market Cap: $456.337 million
Previous Close: $12.25
52 Week Range: $9.74 - $12.74
Volume: 392,654
Avg. Volume: 1,187,350
Recent News:
Introduction:
In the dynamic realm of genetic medicine, where breakthroughs hold the promise of revolutionizing healthcare, one...
KRRO is in the biotechnology space in the gene-editing realm. It is in portfolios of C. Woods .
A recent analyst gave it an upside to 100 which is very favorable given its product line and track
record with an all-time high of about $250 ( which is about 450% over current valuation)
On the one-hour time frame, it has had a great week and is breaking out over...
If you haven`t bought the Double Bottom:
Then you should know that QSI, Quantum-Si incorporated, also known as The Protein Sequencing Company is bringing single-molecule protein sequencing to every lab, everywhere, enabling new discoveries that will transform the world we live in.
Importance of Protein Sequencing:
- Understanding Cellular Processes: Proteins...
$ILMN gapped down
Jan 20 190 P were selling for $7.3+ on gap down
Risk reward worth, took stab
#stocks #options
-
Up 50% in a few minutes
But will hold $ILMN Puts, believe it goes higher
Gap @ 204
On the chance we get put, doubt it, but in the chance, it's in a channel 180 - 240
-
Daily in a nice channel
BNTC Benitec Biopharma Inc is a development-stage biotechnology company which focuses on the development of novel genetic medicines.
The company develops DNA-directed RNA interference based therapeutics.
BlackRock Inc., Renaissance Technologies LLC, Vanguard Group Inc. and Morgan Stanley have stakes in it.
On 2/17/2022 P. Trucchio from HC Wainwright brokerage...
AVROBIO is a clinical-stage gene therapy company to treat rare diseases following a single dose worldwide.
AVRO just released positive data on their Phase 1/2 trial testing the safety and efficacy of AVR-RD-04.
73.42% of the shares are controlled by institutional investors, which gives me a lot of trust in the company.
JPMorgan Chase and BlackRock Inc. have...
BTC Benitec Biopharma is sitting now at a key support from which we can expect a bounce.
We know that earlier this year they had a 7.5mil offering price to the public of $4.25 per share and that Morgan Stanley has a 5.2% stake in the genetic drug company.
Benitec's "proprietary platform, called DNA-directed RNA interference, or ddRNAi, combines RNA...
CRSP CRISPR Therapeutics 52 Week Range 77.42 - 220.20
Now the price is 80.08usd.
Bounced from its last support level.
Barclays has a price target o 148usd for it.
My price target by Q1 2022 is the 100usd resistance.
Looking forward to read your opinion about it.
Technical Analysis
Since early December, we have had over a dozen tails on the purple up-trend arrow drawn in.
The 50sma is now coming into play, as a break below that, could take us another 20% down to the 100sma.
An appropriate level to exit the trade then, would be below the 50sma.
There also horizontal support as we fill the gap.
Important Note:...
CRSP is the leader and pioneer of the CRISPR/CAS9 gene-editing breakthrough. It is a long-term bet as short-term to mid-term future is uncertain.
I think it has one more leg down. Accumulate in the demand zone.
LINK and CRSP have very similar looking charts of a long term ascending triangle breakout that quickly occurred relative to the total length of the triangle. Both have strong fundamentals, each having their place in the 4th industrial revolution. CRSP is on a 2.2x slower timescale than LINK, so LINK may be able to foreshadow price targets on CRSP. Fib extension...
Recent data release may have changed SGMO's future outlook. Sangamo's long-term chart suggests a potential pullback to $4 is a possibility, but that was before a recent data release by the company for updated Phase 1/2 Results for SB-525 . This is an investigational Hemophilia-A gene therapy that showed sustained increased Factor VIII Levels with no reported...
In my previous post on #CRISPR I talked about the Green upward sloping trendline & how every time CRSPR has traded on or below it since May 2017 we've seen parabolic action.
I don't want to say I told you so, but we've seen some parabolic action.
To my surprise, the parabolic movement came the news of Vertex upfront payment of $175 million upfront payment....
Since July 2017, every time CRSP has traded on or below the Green upward sloping trendline CRSP has seen some parabolic action.
Time will tell per usual.
CRSP Gains, gains, more gains. Looking good so far this year. Gene editing seeking to cure diseases and cancer. Don't sleep on this one. Hitting some all time highs right now so wait for a moment to get down to the $22's and $21's and watch for a good return in the future.
